These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1128 related items for PubMed ID: 27485109

  • 1. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G.
    BMC Cancer; 2016 Aug 02; 16():572. PubMed ID: 27485109
    [Abstract] [Full Text] [Related]

  • 2. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
    Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G.
    Oncotarget; 2016 Apr 19; 7(16):21982-90. PubMed ID: 26980736
    [Abstract] [Full Text] [Related]

  • 3. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C, Bianchini M, Bengió R, Larripa I.
    Blood Cells Mol Dis; 2014 Apr 19; 52(2-3):121-5. PubMed ID: 24091144
    [Abstract] [Full Text] [Related]

  • 4. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
    Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, Martinelli G, Stopka T, Ernst T, Hochhaus A, Kohlmann A, Soverini S.
    J Cancer Res Clin Oncol; 2015 May 19; 141(5):887-99. PubMed ID: 25367136
    [Abstract] [Full Text] [Related]

  • 5. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
    Elnair R, Galal A.
    BMC Cancer; 2018 Nov 12; 18(1):1097. PubMed ID: 30419862
    [Abstract] [Full Text] [Related]

  • 6. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W, Thongnoppakhun W, Auewarakul CU.
    Exp Mol Pathol; 2012 Apr 12; 92(2):259-65. PubMed ID: 22314255
    [Abstract] [Full Text] [Related]

  • 7. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR, Yang F, Press RD.
    Methods Mol Biol; 2013 Apr 12; 999():25-39. PubMed ID: 23666688
    [Abstract] [Full Text] [Related]

  • 8. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
    Boeckx N, Laer CV, Roover JD, Wilmsen B, Bruyninckx K, Pauwels S.
    Acta Clin Belg; 2015 Aug 12; 70(4):237-43. PubMed ID: 26166681
    [Abstract] [Full Text] [Related]

  • 9. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
    Kizilors A, Crisà E, Lea N, Passera R, Mian S, Anwar J, Best S, Nicolini FE, Ireland R, Aldouri M, Pocock C, Corbett T, Gale R, Bart-Smith E, Weston-Smith S, Wykes C, Kulasekararaj A, Jackson S, Harrington P, McLornan D, Raj K, Pagliuca A, Mufti GJ, de Lavallade H.
    Lancet Haematol; 2019 May 12; 6(5):e276-e284. PubMed ID: 31036317
    [Abstract] [Full Text] [Related]

  • 10. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L, Ameur A, Häggqvist S, Höijer I, Cahill N, Olsson-Strömberg U, Hermanson M.
    BMC Cancer; 2015 Feb 12; 15():45. PubMed ID: 25880391
    [Abstract] [Full Text] [Related]

  • 11. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
    Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, Haferlach C, Haferlach T.
    Haematologica; 2016 Jul 12; 101(7):830-8. PubMed ID: 27102501
    [Abstract] [Full Text] [Related]

  • 12. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
    McCarron SL, O'Connor LM, Langabeer SE, Conneally E.
    Genet Test Mol Biomarkers; 2013 Feb 12; 17(2):170-3. PubMed ID: 23289634
    [Abstract] [Full Text] [Related]

  • 13. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, O'Hare T, Yan Y.
    Leukemia; 2016 Jul 12; 30(7):1493-501. PubMed ID: 27044711
    [Abstract] [Full Text] [Related]

  • 14. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
    Seman ZA, Ahid F, Kamaluddin NR, Sahid ENM, Esa E, Said SSM, Azman N, Mat WKDW, Abdullah J, Ali NA, Khalid MKNM, Yusoff YM.
    BMC Res Notes; 2024 Apr 20; 17(1):111. PubMed ID: 38643202
    [Abstract] [Full Text] [Related]

  • 15. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
    Shih LY, Kuo MC, Kuo CY, Lin TH, Bai LY, Chen TY, Wang MC, Lin TL, Lan YJ, Chen CC, Yang Y, Hsiao PC, Lai CL, Chang CH, Lin TH.
    Leuk Res; 2013 Jan 20; 37(1):43-9. PubMed ID: 23062378
    [Abstract] [Full Text] [Related]

  • 16. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
    Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP, Branford S.
    J Clin Oncol; 2011 Nov 10; 29(32):4250-9. PubMed ID: 21990409
    [Abstract] [Full Text] [Related]

  • 17. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
    Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, Sica S, Sorà F, Lunghi F, Ciceri F, Galimberti S, Baratè C, Bonifacio M, Scaffidi L, Castagnetti F, Gugliotta G, Albano F, Russo Rossi AV, Stagno F, di Raimondo F, D'Adda M, di Bona E, Abruzzese E, Binotto G, Sancetta R, Salvucci M, Capodanno I, Girasoli M, Coluzzi S, Attolico I, Musolino C, Calistri E, Annunziata M, Bocchia M, Stella S, Serra A, Errichiello S, Saglio G, Pane F, Vigneri P, Mignone F, Laginestra MA, Pileri SA, Percesepe A, Tenti E, Rosti G, Baccarani M, Cavo M, Martinelli G.
    Blood; 2020 Feb 20; 135(8):534-541. PubMed ID: 31877211
    [Abstract] [Full Text] [Related]

  • 18. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
    Razga F, Jurcek T, Zackova D, Dvorakova D, Toskova M, Jeziskova I, Mayer J, Racil Z.
    Mol Diagn Ther; 2012 Aug 01; 16(4):251-9. PubMed ID: 22873741
    [Abstract] [Full Text] [Related]

  • 19. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
    Cayuela JM, Chomel JC, Coiteux V, Dulucq S, Escoffre-Barbe M, Etancelin P, Etienne G, Hayette S, Millot F, Nibourel O, Nicolini FE, Réa D, pour la France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) et le Groupe des biologistes moléculaires des hémopathies malignes (GBMHM).
    Bull Cancer; 2020 Jan 01; 107(1):113-128. PubMed ID: 31353136
    [Abstract] [Full Text] [Related]

  • 20. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
    Int J Clin Oncol; 2017 Oct 01; 22(5):972-979. PubMed ID: 28550414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.